Details of the Drug

General Information of Drug (ID: DM3PDL8)

Drug Name

ARO-ANG3

Indication

Disease Entry	ICD 11	Status	REF
Dyslipidemia	5C80-5C81	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

RNA interference

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ANGPTL3 messenger RNA (ANGPTL3 mRNA)	TT59GO7	ANGL3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04832971) A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia. U.S.National Institutes of Health.
2	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.